
Boehringer Ingelheim and Saniona are advancing to the next stage of their partnership on a drug candidate within the schizophrenia indication, the latter firm announces in a press release on Monday.
According to the company’s founder as well as chief scientific officer, Jørgen Drejer, the collaboration is now ready for a ”hit-to-lead stage,” which follows the successful completion of a target validation, library screening and generation of selective hits.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app